Johannes Nippgen
Overview
Explore the profile of Johannes Nippgen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
1983
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sobrero A, Lenz H, Eng C, Scheithauer W, Middleton G, Chen W, et al.
Oncologist
. 2020 Nov;
26(2):e261-e269.
PMID: 33191588
Background: The multicenter, open-label, randomized, phase III EPIC study (EMR 062202-025) investigated cetuximab plus irinotecan versus irinotecan in patients with epidermal growth factor receptor-detectable metastatic colorectal cancer (mCRC) that progressed...
2.
Hakenberg O, Perez-Gracia J, Castellano D, Demkow T, Ali T, Caffo O, et al.
Eur J Cancer
. 2018 Dec;
107:186-195.
PMID: 30573277
Introduction: Platelet-derived growth factor receptor-α (PDGFRα) is expressed in primary prostate adenocarcinoma and in associated skeletal metastases. Olaratumab is a fully human monoclonal antibody that binds PDGFRα and blocks downstream...
3.
Doi T, Ma Y, Dontabhaktuni A, Nippgen C, Nippgen J, Ohtsu A
Cancer Sci
. 2014 May;
105(7):862-9.
PMID: 24816152
Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-α with high affinity and blocks ligand binding. This was...
4.
Chiorean E, Sweeney C, Youssoufian H, Qin A, Dontabhaktuni A, Loizos N, et al.
Cancer Chemother Pharmacol
. 2014 Jan;
73(3):595-604.
PMID: 24452395
Purpose: The platelet-derived growth factor receptor (PDGFR) has an important role in tumorigenesis and tumor progression. Olaratumab (IMC-3G3) is a fully human monoclonal antibody that selectively binds human PDGFRα and...
5.
Raoul J, Van Laethem J, Peeters M, Brezault C, Husseini F, Cals L, et al.
BMC Cancer
. 2009 Apr;
9:112.
PMID: 19366444
Background: This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses...
6.
Van Cutsem E, Kohne C, Hitre E, Zaluski J, Chang Chien C, Makhson A, et al.
N Engl J Med
. 2009 Apr;
360(14):1408-17.
PMID: 19339720
Background: We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS...
7.
Oliveira-Ferrer L, Hauschild J, Fiedler W, Bokemeyer C, Nippgen J, Celik I, et al.
J Exp Clin Cancer Res
. 2008 Dec;
27:86.
PMID: 19114005
Background: The antiangiogenic agent cilengitide disrupts integrin binding to the extracellular matrix leading to apoptosis of activated endothelial cells. Integrins are also widely expressed in malignant glioma and integrin inhibitors...
8.
Reardon D, Fink K, Mikkelsen T, Cloughesy T, ONeill A, Plotkin S, et al.
J Clin Oncol
. 2008 Nov;
26(34):5610-7.
PMID: 18981465
Purpose: Cilengitide, an inhibitor of alphavbeta3 and alphavbeta5 integrin receptors, demonstrated minimal toxicity and durable activity across a wide range of doses administered to adults with recurrent glioblastoma multiforme (GBM)...
9.
Friess H, Langrehr J, Oettle H, Raedle J, Niedergethmann M, Dittrich C, et al.
BMC Cancer
. 2006 Dec;
6:285.
PMID: 17156477
Background: Anti-angiogenic treatment is believed to have at least cystostatic effects in highly vascularized tumours like pancreatic cancer. In this study, the treatment effects of the angiogenesis inhibitor Cilengitide and...
10.
Berdjis N, Meye A, Nippgen J, Dittert D, Hakenberg O, Baretton G, et al.
BJU Int
. 2005 Jun;
96(1):146-8.
PMID: 15963138
Objective: To investigate the Ki-67 labelling index (LI) as a prognostic factor for the outcome of penile carcinoma, as in squamous cell carcinoma (SCC) of the larynx the expression of...